In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Seeking Focus, Ipsen Turns To Specialty Pharma Model

Executive Summary

Marc de Garidel, Ipsen’s new CEO, is re-focusing the mid-sized French group’s attention on its core commercial assets, trimming the portfolio, and narrowing down early-stage R&D. The de-risking move turns Ipsen sharply in a specialty pharma direction that may please some investors over the near-term, but which raises questions related to the future viability of Ipsen’s R&D engine.

Related Content

Inspiration’s Hemophilia Pact With Ipsen Gets Surprise Revamp
Financial Crunch Time For Inspiration As Hemophilia Pact With Ipsen Gets Surprise Revamp
Ipsen Moves Aggressively On U.S. Strategy, Builds Out Commercial and R&D Infrastructure
Ipsen Extends Inspiration Deal, Appoints New CFO And Updates Sales Forecast
Ipsen's New Chief Outlines Growth Plans In U.S., Emerging Markets
EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
Biogen Idec Charts A New Course
Biogen Idec Charts A New Course
Tercica Gives Ipsen US Foothold
Tercica Gives Ipsen US Foothold

Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts